Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis

Journal of Ovarian Research

Carmen Romero¹  Margarita Vega²  Verónica Tapia²  Carolina Vera³ 

[1] Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile;Departamento de Obstetricia y Ginecología, Facultad de Medicina, Universidad de Chile, Santiago, Chile;Laboratorio de Endocrinología y Biología Reproductiva, Hospital Clínico Universidad de Chile, Santos Dumont # 999, Santiago, Chile

关键词: Epithelial ovarian cancer;    Normal ovary;    TRKA;    Nerve growth factor;    Vascular endothelial growth factor;    Angiogenesis;   

Others  :  1151816
DOI  :  10.1186/s13048-014-0082-6

 received in 2014-05-26, accepted in 2014-08-06,  发布年份 2014

【 摘 要 】

In normal ovarian function a controlled angiogenesis is essential. Several growth factors are involved in this process, such as the vascular endothelial growth factor (VEGF) and nerve growth factor (NGF). The angiogenesis process in the normal ovary is a tightly controlled process that occurs in each ovarian cycle. Also, angiogenesis is critical for ovarian cancer development and it is responsible for tumor spread, metastasis and its peritoneal dissemination. Ovarian cancer is the fifth leading cause of cancer death in women and it is distinguished as the most lethal gynecologic cancer. In recent years angiogenesis has been given considerable attention in order to identify targets for developing effective anti-tumor therapies. Several molecules have been reported to promote angiogenesis, such as platelet-derived growth factor (PDGF) and its receptors, the angiopoietin/Tie ligand/receptor system and fibroblast growth factor (FGF). Primarily, VEGF has been identified to play key roles in driving angiogenesis. The above-mentioned molecules are candidate drug targets. Used in combination with other treatments, anti-angiogenic therapies have managed to reduce disease progression. The present review is focused in NGF and its high affinity receptor tyrosine kinase A (TRKA). The expression of VEGF, proliferation and the angiogenesis process in ovarian cancer is importantly induced by NGF, among other molecules.

【 授权许可】

   
2014 Vera et al.; licensee BioMed Central Ltd

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Reynolds LP, Grazul-Bilska AT, Redmer DA: Angiogenesis in the female reproductive organs: pathological implications. Int J Exp Pathol 2002, 83(4):151-163.
• [2]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
• [3]Julio-Pieper M, Lara HE, Bravo JA, Romero C: Effects of nerve growth factor (NGF) on blood vessels area and expression of the angiogenic factors VEGF and TGFbeta1 in the rat ovary. Reprod Biol Endocrinol 2006, 4:57. BioMed Central Full Text
• [4]Urzúa U, Tapia V, Geraldo MP, Selman A, Vega M, Romero C: Nerve growth factor stimulates cellular proliferation of human epithelial ovarian cancer. Horm Metab Res 2012, 44:656-661.
• [5]Dissen GA, Romero C, Hirshfield AN, Ojeda SR: Nerve growth factor is required for early follicular development in the mammalian ovary. Endocrinology 2001, 142:2075-2086.
• [6]Dissen GA, Hill DF, Costa ME, Dees WL, Lara HE, Ojeda SR: A role for trkA nerve growth factor receptors in mammalian ovulation. Endocrinology 1996, 137:198-209.
• [7]Salas C, Julio-Pieper M, Valladares M, Pommer R, Vega M, Mastronardi C, Kerr B, Ojeda SR, Lara HE, Romero C: Nerve growth factor-dependent activation of trkA receptors in the human ovary results in synthesis of FSH receptors and estrogen secretion. J Clin Endocrinol Metab 2006, 91(6):2396-403.
• [8]Campos X, Muñoz Y, Selman A, Yazigi R, Moyano L, Weistein-Oppenheimer , Lara HE, Romero C: Nerve growth factor and its high-affinity receptor TRKA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer. Gynecol Oncol 2007, 104:168-175.
• [9]Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA: Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003, 9(6):2248-2259.
• [10]Kaplan DR, Stephens RM: Neurotrophin signal transduction by the trk receptor. J Neurobiol 1994, 25:1404-1417.
• [11]Maness LM, Kastin AJ, Weber JT, Banks WA, Beckman BS, Zadina JE: The neurotrophins and their receptors: structure, function, and neuropathology. Neurosci Biobehav Rev 1994, 18:143-159.
• [12]Shibayama E, Koizumi H: Cellular localization of the trk neurotrophin receptor family in human non-neuronal tissues. Am J Pathol 1996, 148:1807-1818.
• [13]Lara HE, Hill DF, Katz KH, Ojeda SR: The gene encoding nerve growth factor is expressed in the immature rat ovary: effect of denervation and hormonal treatment. Endocrinology 1990, 126:357-363.
• [14]Tessarollo L: Pleiotrophic functions of neurotrophins in development. Cytokine Growth Factor Rev 1998, 9:125-137.
• [15]Romero C, Paredes A, Dissen GA, Ojeda SR: Nerve growth factor induces the expression of functional FSH receptors in newly formed follicles of the rat ovary. Endocrinology 2002, 143:1485-1494.
• [16]Mayerhofer AD, Dissen GA, Hill DF, Mayerhofer D, Garfield RE, Costa ME, Costa ME, Skinner MK, Ojeda SR: Involvement of nerve growth factor in the ovulatory cascade: trkA receptor activation inhibits gap junctional communication between thecal cells. Endocrinology 1996, 137(12):5662-5670.
• [17]Anderson RA, Robinson LL, Brooks J, Spears N: Neurotrophins and their receptors are expressed in the human fetal ovary. J Clin Endocrinol Metab 2002, 87:890-897.
• [18]Seifer DS, Feng BO, Shelden RM, Chen S, Dreyfus F: Brain-derived neurotrophic factor: a novel human ovarian follicular protein. J Clin Endocrinol Metab 2002, 87:655-659.
• [19]Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, Giordano T, Peale F: Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol 2003, 162(6):1881-1893.
• [20]Geva E, Jaffe RB: Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 2000, 74(3):429-438.
• [21]Lara HE, Dees WL, Hiney JK, Dissen GA, Rivier C, Ojeda SR: Functional recovery of the developing rat ovary after transplantation: contribution of the extrinsic innervation. Endocrinology 1991, 129:1849-1860.
• [22]Dissen GA, Lara HE, Fahrenbach WH, Costa ME, Ojeda SR: Immature rat ovaries become revascularized rapidly after autotransplantation and show a gonadotropin dependent increase in angiogenic factor gene expression. Endocrinology 1994, 134(3):1146-1154.
• [23]Samii A, Unger J, Lange W: Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neuroscience letters 1999, 262(3):159-162.
• [24]Calza L, Giardino L, Giuliani A, Aloe L, Levi-Montalcini R: Nerve growth factor control of neuronal expression of angiogenic and vasoactive factors. PNAS 2001, 98(7):4160-4165.
• [25]Julio-Pieper M, Lozada P, Tapia V, Vega M, Miranda C, Vantman D, Ojeda SR, Romero C: Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated Kinase 2-dependent pathway. J Clin Endocrinol Metab 2009, 94(8):3065-3071.
• [26]Fathalla MF: Incessant ovulation–a factor in ovarian neoplasia? Lancet 1971, 2(7716):163.
• [27]Auersperg N, Wong A, Choi KC, Kang S: Biology, endocrinology, and pathology. Endocr Rev 2001, 22(2):255-288.
• [28]Fleming J, Beaigié C, Haviv I, Chenevix-Trench G, Tan O: At the cutting edge. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Mol Cell Endocrinol 2006, 247:4-21.
• [29]Mok CH, Tsao SW, Knapp RC, Fishbaugh PM, Lau CC: Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res 1992, 52:5119-5122.
• [30]Kurman R, Shih IM: Progress in pathology-molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm. Hum Pathol 2011, 42:918-931.
• [31]Folkman J: What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 1990, 82:4-6.
• [32]Denekamp J, Hobson B: Endothelial cell proliferation in experimental tumours. Br J Cancer 1982, 461:711-720.
• [33]Folkman J: Angiogenesis and its inhibitors. In Important Adv Oncol: Part I. Edited by DeVita VT, Hellman S, Rosemberg SA. J.B. Lippincott, Philadelphia; 1985:42-62.
• [34]Fraser HM: Regulation of the ovarian follicular vasculature. Reprod Biol Endocrinol 2006, 4:18. BioMed Central Full Text
• [35]Gavalas NG, Liontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, Dimopoulos MA, Bamias A: Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci 2013, 14(8):15885-15909.
• [36]Coxon A, Bready J, Min H, Kaufman S, Leal J, Yu D, Lee TA, Sun J-R, Estrada J, Bolon B, McCabe J, Wang L, Rex K, Caenepeel S, Hughes P, Cordover D, Kim H, Han SH, Michaels ML, Hsu E, Shimamoto G, Cattley R, Hurh E, Nguyen L, Wang SX, Ndifor A, Hayward IJ, Falcón BL, McDonald DM, Li L, et al.: Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010, 9(10):2641-2651.
• [37]Fearon AE, Gould CR, Grose RP: FGFR signalling in women’s cancers. Int J Bioquem Cell B 2013, 45(12):2832-2842.
• [38]Kigawa J: New strategy for overcoming resistance to chemotherapy of ovarian cancer. Yonago Acta Med 2013, 56(2):43-50.
• [39]Eskander RN, Tewari KS: Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-Mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014, 132(2):496-505.
• [40]Nakagawara A: Trk receptor tyrosine kinase: a bridge between cancer and neural development. Cancer Letters 2001, 169:107-114.
• [41]Mc Gregor LM, Mc Cune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB, Nelkin BD: Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 1999, 96:4540-4545.
• [42]Oelmann E, Srete L, Schuller I, Serve H, Koenigsmann M, Wiedenmann B, Oberberg D, Reufi B, Thiel E, Berdel WE: Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling. Cancer Res 1995, 55(10):2212-2219.
• [43]Zhu ZW, Friess H, Wang L, Di Mola F, Zimmermann A, Buchler MW: Down-regulation of nerve growth factor in poorly differentiates and advanced human esophageal cancer. Anticancer Res 2000, 20:125-132.
• [44]Sortino MA, Condorelli F, Vancheri C, Chiarenza A, Bernardini R, Consoli U, Canonico PL: Mitogenic effect of nerve growth factor (NGF) in LNCaP prostate adenocarcinoma cells: role of the high and low affinity NGF receptors. Mol Endocrinol 2000, 14:124-136.
• [45]Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G, Cecilia Melani C, Ménard S: Nerve growth factor cooperates with p185 (HER2) in activating growth of human breast carcinoma cells. J Biol Chem 2000, 275:5388-5394.
• [46]Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R: Expression levels of the nerve growth factor receptors trkA and p75 in effusions and solid tumor of serous ovarian carcinoma patients. Clin Cancer Res 2001, 7:3457-3464.
• [47]Tisher E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
• [48]Ferrara N, Daves-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:3-25.
• [49]Park JE, Keller GA, Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: differential disposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4:1317-1326.
• [50]Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T: Biological implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 1998, 83:2528-2533.
• [51]Stimpfl M, Tong D, Fashing B, Schuster E, Obermair A, Leodolter S, Zeillinger R: Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Cancer Res 2002, 8:2253-2259.
• [52]Chesa PG, Rettig WJ, Thomsom TM, Old LJ, Melamed MR: Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. J Histochem Cytochem 1988, 36:383-389.
• [53]Tapia V, Gabler F, Muñoz M, Yazigi R, Paredes A, Selman A, Vega M, Romero C: Tyrosine kinase A receptor (trkA): A potential marker in epithelial ovarian cancer. Gynecol Oncol 2011, 121:13-23.